Abstract
Cutaneous T-cell lymphomas (CTCLs) in advanced stages and adult T-cell leukemia-lymphoma (ATL) are fatal malignancies. Because therapeutic trials using different combination chemotherapies to improve the poor prognosis of these diseases have been unsatisfactory, an alternative therapeutic approach, hematopoietic stem cell transplantation (HSCT), has been tried. Although autologous HSCT after high-dose chemotherapy has yielded disappointing results, a better therapeutic outcome was obtained with allogeneic HSCT. As allogeneic HSCT induce GVHD by eliciting cellular immune responses of donors against recipient cells, graft-versus-lymphoma effects play a beneficial role.[Skin Cancer (Japan) 2009 ; 24 : 510-515]
